Hansa Biopharma granted SERB Pharmaceuticals exclusive rights to develop and commercialize IDEFIRIX (imlifidase) across the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA for total consideration of €115M (~$128M USD). IDEFIRIX is the first-in-class IgG-cleaving enzyme conditionally authorized in Europe for desensitization of highly sensitized kidney transplant patients with positive crossmatch.
Key facts
AnnouncedMay 19, 2026
Deal value$134M
Deal typeLicensing/Option
Therapeutic areaDesensitization in highly sensitized adult kidney transplant patients
IndicationsDesensitization in highly sensitized adult kidney transplant patients
Key assetsIDEFIRIX (imlifidase)
MechanismIgG-degrading enzyme of Streptococcus pyogenes (IdeS) that cleaves all IgG subclasses within hours